The Effect of Distal Versus Proximal iPACK on Pain After Total Knee Arthroplasty
NCT ID: NCT07080892
Last Updated: 2025-07-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
120 participants
INTERVENTIONAL
2025-02-12
2027-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Analgesic Efficacy of Protocol for Primary Total Knee Arthroplasty (TKA)
NCT03703206
Adductor Canal Block and IPACK Block vs Adductor Canal Block and the Gastrosoleus Interfascial Block After Total Knee Arthroplasty
NCT07336901
Comparison Between the Effect of Infiltration Between the Popliteal Artery and Capsule of the Knee Block Versus Selective Tibial Nerve Block for Postoperative Analgesia in Patient Undergoing Total Knee Arthroplasty. A Prospective Randomized Study
NCT05473559
Comparison of Distal IPACK and Popliteal Plexus Block Combined With Femoral Triangle Block After Total Knee Arthroplasty
NCT07130552
Genicular vs IPACK Block for Analgesia in Knee Arthroplasty
NCT07171931
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To minimize motor deficits while still providing effective pain relief, newer regional anesthesia techniques have been introduced into clinical practice. One such technique is the iPACK block (interspace between the popliteal artery and posterior capsule of the knee), which targets the posterior knee - an area often insufficiently covered by conventional nerve blocks. This method involves administering a local anesthetic into the space between the popliteal artery and the posterior capsule of the knee joint, offering analgesia without significant motor impairment.
Originally, the iPACK block was described as being performed at the level of the distal femoral shaft, several centimeters above the femoral condyles. Recently, however, a more distal variation of the technique has emerged, where the anesthetic is injected directly between the femoral condyles. This may provide more effective coverage of the posterior knee capsule's innervation. To date, there are no randomized trials that directly compare the efficacy of the distal and proximal iPACK approaches in terms of postoperative pain as the primary outcome.
Our aim is to conduct a prospective, randomized, placebo-controlled, double-blind clinical trial to compare the effectiveness of the distal and proximal iPACK blocks in patients undergoing TKA. A total of 120 patients will be enrolled and randomly assigned to one of two groups.
* In the proximal iPACK group, participants will receive 20 ml of 0.25% levobupivacaine with adrenaline (1:200,000), injected at the level of the distal femoral shaft (a straight portion of the femur without the condyles).
* In the distal iPACK group, the same volume and concentration of anesthetic will be injected at the most distal part of the thigh, between the femoral condyles.
All participants, regardless of group assignment, will also receive an adductor canal block with 20 ml of 0.25% levobupivacaine without adrenaline. In addition, all patients will receive standard analgesic therapy consisting of paracetamol (1 g IV every 8 hours) and diclofenac (75 mg IV every 12 hours). If necessary, rescue opioid doses will be available according to individual needs.
The efficacy of each approach will be assessed using several parameters: pain intensity will be measured using the Visual Analogue Scale (VAS) both at rest and during active knee movement (up to 45 degrees) at 6, 12, and 24 hours postoperatively. Secondary outcomes include total opioid consumption within 24 hours and time to first opioid rescue dose.
The hypothesis of our study is that the distal iPACK approach will provide more effective postoperative pain control compared to the original proximal technique. If confirmed, the findings could influence perioperative pain management protocols for TKA, support the broader adoption of the distal iPACK block in clinical practice, enhance patient comfort, reduce opioid use, promote earlier mobilization, and potentially shorten hospital stays.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
proximal iPACK group
In the proximal iPACK group, participants will receive 20 ml of 0.25% levobupivacaine with adrenaline (1:200,000), injected at the level of the distal femoral shaft (a straight portion of the femur without the condyles).
proximal iPACK
● In the proximal iPACK group, participants will receive 20 ml of 0.25% levobupivacaine with adrenaline (1:200,000), injected at the level of the distal femoral shaft (a straight portion of the femur without the condyles).
distal iPACK group
In the distal iPACK group, the participants will receive 20 ml of 0.25% levobupivacaine with adrenaline (1:200,000), injected at the most distal part of the thigh, between the femoral condyles.
distal iPACK
● In the distal iPACK group, participants will receive 20 ml of 0.25% levobupivacaine with adrenaline (1:200,000), injected at the most distal part of the thigh, between the femoral condyles.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
distal iPACK
● In the distal iPACK group, participants will receive 20 ml of 0.25% levobupivacaine with adrenaline (1:200,000), injected at the most distal part of the thigh, between the femoral condyles.
proximal iPACK
● In the proximal iPACK group, participants will receive 20 ml of 0.25% levobupivacaine with adrenaline (1:200,000), injected at the level of the distal femoral shaft (a straight portion of the femur without the condyles).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients undergoing primary unilateral total knee arthroplasty (TKA) for osteoarthritis
* Ability to understand and sign informed consent
* American Society of Anesthesiologists (ASA) classification I-III
* Ability to cooperate and participate in postoperative pain assessments (e.g., VAS)
Exclusion Criteria
* Bilateral or revision TKA
* Partial or unicondylar knee replacement
* Severe knee deformity (flexion, varus, or valgus \>30°)
* Diagnosis other than osteoarthritis (e.g., rheumatoid arthritis, septic arthritis, post-traumatic arthritis)
* Allergy to local anesthetics or any medications used in the study
* Contraindications to regional anesthesia (e.g., infection at the injection site, coagulopathy, therapeutic anticoagulation)
* BMI \> 40 kg/m²
* Severe renal impairment (KDIGO stage G4 or higher) or liver failure (Child-Pugh score ≥ 10)
* Prior surgery or vascular procedure on the femoral vessels of the operated limb
* Language barrier or inability to assess pain using the VAS
* Planned outpatient (same-day discharge) procedure
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Comenius University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
1st Department of Anaesthesiology and Intensive Care Medicine
Bratislava, , Slovakia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UNB/RU/052025
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.